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Abstract IL-9 was initially identified as a Tcell growth factor
with a potential oncogenic activity. Accordingly, IL-9 drives
tumor growth in most hematological cancers. However, the
links between IL-9 and cancer progression have been recently
revisited following the discovery of TH9 cells. TH9 cells,
which have been characterized in 2008 as a proinflammatory
CD4 T cell subset that promotes protection against parasites
and drives tissue inflammation in colitis, actually harbor po-
tent IL-9-dependent anti-cancer properties in solid tumors and
especially melanoma. While the molecular mechanisms un-
derlying these observations are still being investigated, TH9
cells were demonstrated to activate both innate and adaptive
immune responses, thereby favoring anti-cancer immunity
and tumor elimination. Human TH9 cells have also been iden-
tified in cancer tissues, but their functions remain elusive. The
present review aims to discuss the anti-cancer potential of TH9
cells and their possible clinical relevance for cancer
immunotherapy.
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Introduction
In 1893, William Coley and Robert Koch reported that the
injection of streptococcal cultures into cancer patients drove
tumor regression [1]. This was actually the first indication that
the activation of the immune system was able to lead to tumor
elimination. The development of cellular immunology then
led Burnet to propose in 1957 the cancer immunosurveillance
hypothesis, which postulates that developing tumor cells trig-
ger an immune reaction that drives their elimination by im-
mune cells before forming a clinically detectable tumor. It
remained however difficult to understand why despite the ex-
istence of spontaneous immune responses to tumor antigens,
this reaction failed to control tumor growth. Subsequent stud-
ies unraveled that the immune cells could play a dual role in
cancer. They can either prevent tumor growth by eliminating
tumor cells or drive tumor progression by favoring the emer-
gence of tumor clones resistant to anti-tumor immunity and
creating tumor promoting conditions in the tumor microenvi-
ronment. The latter concept named cancer immunoediting il-
lustrates the ability of immune cells to shape tumor progres-
sion. The relevance of cancer immunoediting was confirmed
not only in preclinical studies but also in humans [2]. Indeed,
most human tumors infiltrated with either regulatory or effec-
tor immune cells are, respectively, associated with a worse and
more favorable prognosis as reviewed elsewhere [3].
CD4 T cells display a high degree of plasticity and the
ability to differentiate into various effector and regulatory T
cell subsets that express distinct transcription factors and se-
crete different cytokine panels. CD4 cells actively participate
in shaping anti-tumor immunity. TH1 and TH2 cells were the
first-defined TH lineages by Mosmann and Coffman in 1986.
TH1 cells are ascribed with anti-cancer functions, notably be-
cause these cells secrete high levels of IFN-γ, which prevents
tumor angiogenesis, enhances tumor cell immunogenicity by
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upregulatingMHC class I and II expression, promotes recruit-
ment of immune cells including CD8 T and NK cells that
mediate tumor-killing activity, and increases the anti-tumor
activity of macrophages [4–6]. Conversely, TH2 cells are as-
sociated with the promotion of tumor growth. This activity is
primarily due to their secretion of IL-4 and IL-13 cytokines,
which enhance tumor cell survival [7, 8]. Nevertheless, this
initial dichotomy in TH subsets failed to explain the complex-
ity of CD4 T cell responses and the existence of additional
CD4 T helper subsets was investigated, ultimately leading to
the identification of other TH subsets, including regulatory T
cells (Tregs), TH17 cells, and Tr1 cells. Tregs and Tr1 cells
suppress immune responses, favor the maintenance of im-
mune tolerance, and contribute to tumor progression in the
vast majority of cancers [9, 10]. The role of TH17 cells in
cancer progression is controversial [6, 11]. TH17 cell-derived
IL-17A favors tumor progression and neoangiogenesis. In ad-
dition, IL-17A triggers STAT3 activation in tumor cells, there-
by favoring tumor growth [12]. However, in mouse models of
melanoma, it was conversely shown that the adoptive transfer
of TH17 cells could restrain tumor progression [13, 14]. The
complex relationships between TH17 cells and cancer progres-
sion are further illustrated by observations in humans showing
that TH17 cell infiltration is detrimental in colon cancer but
beneficial in ovarian cancer [11]. Thus, CD4 Tcell subsets and
their associated cytokines can have profound effects on tumor
progression.
In 2008, one novel CD4+ Tcell subset secreting high levels
of IL-9 was characterized and named TH9 cells. This CD4
+ T
cell subset was simultaneously discovered by two different
laboratories [15, 16]. Veldohen et al. showed that TGFβ was
able to reprogram the differentiation of TH2 cells into IL-9
producing T cells, while Dardalhon et al. demonstrated that
IL-4 is able to block Foxp3 induction in Treg cells, thereby
inducing a population of T helper cells that predominantly
produce IL-9 [15, 16]. The discovery of TH9 cells thus further
illustrates the plasticity among CD4+ T cells. The role of IL-9
in cancer has been previously explored. By generating trans-
genic mice overexpressing the Il9 gene, Renauld and col-
leagues found that a small proportion of IL-9 overexpressing
mice developed thymic lymphomas, suggesting that IL-9 sup-
ports the development of T cell tumors [17]. This observation
was actually in line with the previously ascribed activity of IL-
9 as a T cell growth factor [18]. IL-9 was then shown to
promote the development of many hematological human tu-
mors, including Hodgkin’s lymphoma and B cell lymphoma
[19]. In addition, IL-9 was proposed to enhance the immuno-
suppressive functions of Tregs and to block the establishment
of adaptive anti-tumor immunity by preventing the develop-
ment of immunologic memory [20, 21].
While the aforementioned findings suggest that IL-9 can
drive tumor progression, several investigators found that TH9
cells harbored anti-cancer properties in solid tumors, including
lung adenocarcinoma and melanoma. Importantly, these anti-
cancer properties were found to depend, at least in part, on
TH9 cell-derived IL-9. In addition, TH9 cells were identified in
human melanoma skin lesions, suggesting that they could
possibly contribute to cancer immunosurveillance in this dis-
ease. In this review, we discuss recent findings that provide
strong impetus to revisit the links between IL-9 and cancer
progression and highlight the relevance of modulating TH9
cell functions for cancer immunotherapy.
TH9 cell-driven activation of innate anti-cancer
immunity
The seminal investigation on the role of TH9 cells in cancer
was carried out by Purwar and colleagues who investigated
the anti-tumor properties of TH9 cells in a mouse model of
melanoma. Specifically, they tested the ability of tumor-
specific CD4 T cells polarized into TH9 cells or other effector
CD4 T cell subsets to prevent tumor outgrowth in B16 tumor-
bearing mice upon adoptive transfer. They found that TH9
cells were highly efficient in preventing tumor progression
in this setting. Importantly, the anti-cancer efficacy of TH9
cells was superior to all other CD4 T cell subsets tested, in-
cluding TH1 and TH17 cells [22]. Upon studying the mecha-
nism responsible for the anti-tumor activity of TH9 cells in
melanoma, the authors found, in contrast to published studies
in hematological cancers, that IL-9 blockade using neutraliz-
ing antibodies prevented the beneficial effect of adoptive TH9
cell transfer, underscoring the anti-tumor role for IL-9 in this
setting.
The role of IL-9 in preventing melanoma cell growth was
further explored in IL-9 receptor-deficient mice, and it was
found that B16 tumor cells featured faster growth in vivo in
the absence of IL-9 receptor signaling. Conversely, injection
of recombinant IL-9 protein into wild-type mice impaired B16
tumor cell growth in vivo [22]. Interestingly, the anti-cancer
effect of IL-9 was not restricted to melanoma as injection of
recombinant IL-9 protein into Lewis lung carcinoma tumors
also limited cancer growth [22]. Because IL-9 was not affect-
ing melanoma or lung carcinoma cell proliferation in vitro,
Purwar and colleagues have investigated whether host im-
mune cells were responsible for the anti-cancer effect of IL-
9 in vivo. Authors first tested whether the anti-tumor efficacy
of TH9 cells was dependent on T cell immune responses from
the host upon adoptive transfer. For this, they injected TH9
cells into tumor-bearing Rag1-deficient mice, which lack T
and B cells, and found that the anti-tumor potential of TH9
cells was conserved in the absence of adaptive immunity. It is
noteworthy that these results are supported by another study
showing that the regulation of TH9 cell differentiation by the
transcription factor Id3 regulated anti-melanoma immunity in
an IL-9-dependent manner but without affecting TH1 cell
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responses [23]. In line with this, the anti-tumor effects of re-
combinant IL-9 administration were conserved in tumor-
bearing Rag1-deficient mice, suggesting that other immune
effectors are involved in the anti-cancer effects observed.
IL-9 has been previously shown to trigger mast cell activa-
tion [24]. To study the contribution of mast cells to the anti-
cancer effects triggered by IL-9 administration in vivo, the
authors treated LLC1 and B16 tumor-bearing kit W-sh mice
with IL-9 and found that the anti-tumor effects of IL-9 relied
on mast cells in both tumor models [22, 25]. The role of mast
cells in mediating TH9 cell-dependent anti-tumor immune re-
sponses was further investigated in an elegant study from
Abdul-Wahid et al., who interrogated the cellular bases ac-
counting for the anti-tumor efficacy of a vaccine containing
the carcinoembryonic antigen (CEA) IgV-like N domain and
the toll-like receptor 3 ligand poly I:C that elicited TH9 cell
responses in vivo. In this setting, the importance of TH9 cell
responses in mediating anti-tumor immunity following vacci-
nation of CEA transgenic mice was shown by demonstrating
that IL-9 neutralization prevents the ability of the vaccine to
protect mice against a challenge of live colon carcinoma
MC38.CEA cells. In this setting, the authors found that
treating mice with cromoglycate, which prevents mast cell
activity, or with anti-CD117 antibodies, which deplete mast
cells, abrogated the anti-cancer efficacy of the vaccine [26].
Overall, these results illustrate that TH9 cells can enhance mast
cell activity through IL-9 secretion, resulting in tumor growth
prevention (Fig. 1).
TH9 cell-driven activation of adaptive anti-cancer
immunity
While IL-9 promotes the activation of innate immune cells
like mast cells, which can then contribute to tumor growth
prevention, other studies clearly suggest that the anti-tumor
activity of IL-9 is not only due to the activation of innate
immune effectors. In this regard, upon studying the ability of
TH9 cell transfer to prevent the development of lung tumor
foci in mice injected i.v. with B16 tumor cells, Lu et al. found
enhanced leukocyte infiltration in lung tumor tissues [27].
Specifically, increased infiltration with CD4 and CD8 cells
as well as dendritic cells (DCs) was noted, thereby suggesting
the induction of an adaptive immune response. This hypothe-
sis was further reinforced by the observation that CD44 ex-
pression on T cells was upregulated in mice receiving TH9
cells. They further found that TH9 cells also drove Ccl20/
Ccr6-dependent recruitment of DCs to the tumor tissues,
thereby driving CD8 Tcell activation (Fig. 1). To test whether
CD8 T cells were involved in the TH9 cell anti-tumor effect,
the authors first assessed the frequency of tumor-specific CD8
T cells in mice having received TH9 cells. They found in-
creased frequencies of tumor-specific CD8 Tcells in the tumor
tissues, in contrast to control mice or TH1-treated mice. The
critical contribution of CD8 T cells in mediating the anti-
cancer effects of the transferred TH9 cells was eventually con-
firmed by depleting CD8 Tcells using anti-CD8 antibodies. In
this setting, the injection of anti-CD8 antibodies nullified the
anti-tumor efficacy of TH9 cell transfer in vivo. The ability of
TH9 cell-derived IL-9 to drive the activation of anti-cancer
CD8 T cells was further confirmed recently as illustrated by
Zhao et al., who found that immunization of tumor-bearing
mice with dectin-1-activated DCs induced potent anti-tumor
responses that depended on Th9 cells and the IL-9-dependent
induction of anti-cancer CD8 T cells [28].
We have also explored the anti-cancer efficacy of TH9 cell
transfer in vivo in the B16 melanoma model. In agreement
with Lu et al., we also found that the anti-cancer effects of
TH9 cell transfer were dependent on CD8 T cells in vivo.
Upon investigating the role of proinflammatory factors on
TH9 cell differentiation, we found that IL-1β actually en-
hanced TH9 cell induction, as illustrated by increased IL-9
secretion from TH9 cells [29]. We also found that IL-1β en-
hanced IL-21 secretion levels from differentiating TH9 cells
[29]. These observations relied on the STAT1-dependent acti-
vation of the interferon regulatory factor 1 (IRF1) transcrip-
tion factor, which bound to the IL-9 and IL-21 promoters in
differentiating TH9 cells. Upon investigating the anti-cancer
properties of TH9 cells differentiated in the presence of IL-1β,
we noted that IL-21 was critical in driving the anti-tumor
effects of TH9 cells upon adoptive transfer in vivo. IL-21
drove IFN-γ secretion from both NK and CD8 T cells, which
were both responsible for tumor elimination. Altogether, these
studies suggest that TH9 cells trigger IL-9 and IL-21-depen-
dent, CD8-dependent anti-tumor responses that favor tumor
elimination. It is noteworthy that beyond IL-9 and IL-21, TH9
cell-derived IL-3 could additionally contribute to the induc-
tion of adaptive anti-cancer immune responses. It has indeed
been reported that TH9 cell-derived IL-3 could favor DC sur-
vival [30] (Fig. 1).
While most of the pioneer studies showing the anti-cancer
efficacy of TH9 cells relied on adoptive transfer settings, TH9
cells were recently shown in two studies to be responsible for
anti-cancer immune responses following engagement of
glucocorticoid-induced TNFR-related protein (GITR) [31,
32], a costimulatory molecule present on T cells (Fig. 2). By
studying the expression of Il9 in CT26 colon adenocarcinoma
tumor-bearing mice treated with an agonistic anti-GITR anti-
body (DTA-1), Kim et al. found that the engagement of GITR
was associated with strong IL-9 expression in the tumor-
draining lymph nodes [31]. They next identified TH9 cells as
the major source of IL-9 in this tumor model in response to
DTA-1 treatment. They found that neutralization of IL-9 ab-
rogated the beneficial anti-tumor effect of DTA-1.
Importantly, the authors found that DTA-1 also prevent tumor
development in an IL-9-dependent manner in non-
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transplantable models, including a chemical-induced colorec-
tal cancer and the spontaneous K-Ras transgenic mouse
model. Kim and colleagues then investigated the role of
CD8 T cell responses in the IL-9-dependent anti-cancer effi-
cacy of the DTA-1 treatment. They found that blockade of IL-
9 partly prevented the cytotoxic activity of CD8 T cells.
Interestingly, they also noted that DTA-1 enhanced IL-21 se-
cretion from CD4 T cells in an IL-9-independent manner and
proposed that DTA-1 enhances anti-tumor responses through
TH9 cell-derived IL-9 and, possibly, IL-21 (Fig. 2). Overall,
these results indicate that in the context of lung adenocarcino-
ma, colon carcinoma, and melanoma, TH9 cells promote acti-
vation of adaptive anti-tumor immune responses through their
secretion of IL-9 and IL-21 (Fig. 1).
TH9 cell cytotoxicity on cancer cells
While it is clear that TH9 cells promote the activation of innate
and adaptive immune responses, the ability of TH9 cells to
directly trigger cancer cell death remains debated. Initially,
Purwar et al. showed that unlike TH0 and TH17 cells, TH9 cells
derived fromOT-II transgenic mice, which express a transgenic
T cell receptor able to recognize chicken ovalbumin-derived
peptides, killed ovalbumin-expressing (B16-OVA) tumor cells.
They further noted that TH9 cells expressed high levels of
granzyme-B and that its inhibition reduced the ability of TH9
cells to kill melanoma cells [22]. By contrast, others failed to
note any direct cytotoxicity of TH9 cells on tumor cells in vitro
[27]. Nevertheless, the cytotoxic properties of TH9 cells were
also shown in a mouse model of squamous cancer [33], sug-
gesting that the cytotoxic activity of TH9 cells may be context



























Fig. 2 Signaling pathways that promote interleukin-9 and interleukin-21
production
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Fig. 1 Pleiotropic effects of TH9 cells in anti-tumor immunity
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inhibit proliferation of two human melanoma tumor cell lines
through upregulation of p21 and TRAIL [34], giving additional
impetus to investigate further the direct cytotoxic effects of IL-
9 on cancer cells (Fig. 1).
TH9 cell stability in vivo in a cancer setting
The use of an Il9 mouse reporter model suggested that, in a
model of acute lung injury induced by papain, IL-9 production
was transient in vivo [35]. In line with this, while the antigenic
stimulation of mouse TH9 cells in vitro resulted in a steady
increase in IL-10 secretion, IL-9 levels peaked 3 days following
stimulation but then sharply decreased, thereby questioning
TH9 cell stability [36]. In vivo, TH9 cells have accordingly been
reported to be unstable in some autoimmune disease models,
and TH9 cells recovered from inflamed sites or LNs produced
predominantly IFN-γ [16, 36, 37]. These observations can like-
ly be attributed to the inflammatory environment, since several
cytokines, including IFN-γ or IL-23, can alter TH9 cell pheno-
type or reduce IL-9 production [22, 37–39].
Despite the aforementioned findings, Lu et al. demonstrated
in a cancer setting that TH9 cells were able to retain their cyto-
kine expression profile in vivo [27]. They observed following
adoptive transfer into tumor-bearing mice that TH9 cells main-
tained their IL-9 and IL-10 production in the tumor-draining
lung lymph node (LLN) without switching to IFN-γ or IL-17
producers. Interestingly, there were high levels of IFN-γ pro-
duction in the LLNs of mice receiving TH9 cell transfer, indi-
cating that not only was IFN-γ derived from host cells but also
that transferred TH9 cells induced activation of host immune
effector cells. Importantly, IFN-γ and IL-17 were detected in
the lungs of TH9 cell-transferred mice, whereas these cytokines
were absent in the lungs of TH1 cell-transferred mice. These
results suggest that TH9 cells not only induce effector cell acti-
vation in the tumor-draining lymph nodes but also recruit them
into the tumor site to exert their tumor-killing functions. To
further test whether TH9 cells maintained their phenotype
in vivo, the authors labeled tumor-specific TH9 cells with
CFSE and transferred them to tumor-bearing mice. On day 4,
after transfer, CFSE+ TH9 cells retained their production of IL-
9 and IL-10, with very low amounts of IFN-γ, TNF-α, and IL-
17 secreted, thereby showing that transferred TH9 cells main-
tained their IL-9 and IL-10 cytokine production and did not
convert to TH1 or TH17 cell subsets.
We have also studied the fate of TH9 cells in tumor-bearing
mice in vivo to assess their stability. For this, we transferred
IL-1β-induced CD45.2+ OT-II TH9 cells into CD45.1
+ mice
bearing B16-OVA tumors. We sorted CD45.2+ cells from
lung-draining lymph nodes and analyzed their gene-
expression profiles 6 days after transfer. Importantly,
CD45.2+ cells maintained their expression of TH9-related
genes such as Irf4, Spi1, Il9, and Il21 and did not gain
expression of TH1-related genes after transfer [29]. These data
indicated that IL-1β-induced TH9 cells maintained their tran-
scriptional program in vivo. We speculate that the IL-1β-
induced expression of IRF1 contributes to stabilize the TH9
cell transcriptional program. Altogether, this suggests that in a
cancer setting, TH9 cells are capable of maintaining IL-9- and
IL-21-secreting potential, at least long enough to carry out
their anti-cancer functions in vivo. These observations may
prove relevant in the context of vaccination because a protec-
tive TH9 cell-specific anti-cancer response could be induced
through immunization against tumor antigens [26]. Whether
vaccination protocols could be optimized to induce stable and
specific TH9 memory anti-tumor cells remains to be
determined.
The role of TH9 cells in human cancers
The suggested superiority of TH9 cells in controlling tumor
progression in vivo in mice upon adoptive transfer and the
detection of memory TH9 cells in healthy human blood and
skin underscore the potential relevance of this subset in cancer
immunotherapy [22]. Schlapbach and colleagues further char-
acterized human IL-9-producing T cells [40]. In humans, IL-9
is primarily produced by a discrete and stable population of T
cells. Unlike human and mouse T cells generated by differen-
tiation from naïve cells in vitro, human TH9 cells isolated from
human blood and tissues lacked expression of other TH line-
age cytokines; co-produced TNF-α, granzyme B; and lacked
FOXP3 expression. Both the circulating and the in vitro dif-
ferentiated TH9 cells lacked IL-10 production, a feature that
distinguishes them from mouse TH9 cells. To sort human
memory skin and gut tropic TH cells, Clark and colleagues
used an elegant approach based on the expression of the
skin-homing receptor cutaneous lymphocyte antigen (CLA)
and the gut-homing receptor integrin α4β7. In healthy adults,
TH9 cells were found primarily among the CLA
+ skin-homing
effector T cell population and were present in healthy human
skin but were absent from human small intestine and lung
[40]. In line with their role in inflammation and skin tropism,
TH9 cells were proposed to be involved in the pathogenesis of
respiratory epithelial adenomatoid hamartoma (REAH).
Accordingly, in REAH tissue, TH9 cell population was ex-
panded, the synthesis of IL-9-encoding mRNA upregulated,
and IL-9 secretion increased, suggesting that TH9 cells play a
role in the pathogenesis of the disease [41].
The direct involvement of human TH9 cells in malignancy
remains elusive. TH9 cell numbers were found to be increased
in malignant pleural effusion (MPE) when compared with
blood [42]. Accordingly, Shi et al. reported that the recruit-
ment of TH9 cells into MPE could be induced by pleural
CCL20 expression and that the majority of TH9 cells
expressed a high level of CCR6 on their surface and displayed
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an effector memory phenotype characterized by high expres-
sion of CD45RO and very low levels of CD45RA and CD62L
[43]. In this context, it was shown that the increase in pleural
TH9 cells predicted reduced survival in patients with MPE
[42]. These findings contrast with other studies suggesting
anti-cancer functions for TH9 cells. Specifically, TH9 cells
were found in metastatic lesions of human patients with mel-
anoma. The subsequent analysis of TILs extracted from these
metastatic lesions revealed detectable levels of IL-9-
producing CD4 T cells, lacking IFNγ, IL-4, and IL-17 pro-
duction. However, TH9 cells were less abundant in the TILs
from these melanoma lesions compared to healthy skin, and
their IL-9 secretion was also reduced [22], possibly suggesting
that human TH9 cells are protective against melanoma devel-
opment. Interestingly, IL-9 was recently shown to promote the
survival and function of human melanoma-infiltrating CD4+
CD8+ double-positive T cells [44] (Fig. 1), lending further
support to the hypothesis that IL-9 may amplify anti-tumor
immune responses by promoting T cell fitness in human mel-
anoma. Accordingly, single-nucleotide polymorphisms in the
IL-9 gene are associated with an increased risk of cutaneous
malignant melanoma [45]. These findings suggest that strate-
gies favoring the generation of TH9 cell-mediated immune
responses may have an important role in the treatment of mel-
anoma in humans. In the light of the latest advances on TH9
cell anti-tumor properties [28, 32], the use of dendritic cell-
based therapeutic cancer vaccines could be considered to gen-
erate a TH9 cell response in cancer patients. Indeed, DC-
expressing GITR-L [46] or activated via the dectin-1 signaling
pathway [28] may generate a TH9 cell anti-tumor response
that ultimately results in a clinical benefit in cancer patients.
Conclusions and prospects
TH9 cells have an important role in tumor immunity that
seems to be largely due to their ability to secrete IL-9 and
IL-21 cytokines. IL-9 is a pleiotropic cytokine that can have
direct anti-tumor effects or can indirectly influence tumor
growth by enhancing immune responses. IL-21 likewise
strongly supports the activation of adaptive anti-cancer immu-
nity. Whereas growing evidence supports the potential rele-
vance of TH9 cells to cancer immunity especially in the con-
text of adoptive cell therapy strategies, a complete understand-
ing of the physiological conditions that lead to the generation
and expansion of this particular helper T cell subset is still
lacking [47, 48]. Unraveling the mechanisms that underpin
therapeutic resistance to TH9 cells in tumor-bearing hosts
and/or combining TH9 cell-based therapies with immunomod-
ulators or chemotherapy could promote potent and long-
lasting anti-tumor immunity [49]. Finally, determining wheth-
er the anti-cancer properties of human TH9 cells extend be-
yond the melanoma setting is essential.
TH9 cells harbor strong anti-cancer properties in the
context of solid tumors. Through the production of gran-
zyme-B, TH9 cells trigger cancer cell death [22]. TH9-
derived IL-9 leads to upregulation of p21 and TRAIL,
thus inducing tumor cell cycle arrest and apoptosis upon
activation of IL-9R [34]. TH9 cells are also able to pro-
mote the activation of innate cells [22, 23]. Accordingly,
IL-9 enhances the anti-tumor activity of mast cells [22,
25, 26]. TH9 cells enhance the induction of anti-tumor
adaptive immune responses. IL-9 promotes Ccl20 expres-
sion from epithelial cells, thus driving Ccl20/Ccr6-
dependent leucocyte and DC recruitment [27]. Moreover,
TH9 cell-derived IL-9 enhances IFN-γ secretion from
CD8 T cells [28], while TH9-derived IL-3 can promote
DC survival [30]. IL-21 drives IFN-γ secretion from both
NK and CD8 T cells, which are both responsible for tu-
mor elimination [29].
The regulation of TH9 cell differentiation by the transcrip-
tion factor Id3 influences anti-melanoma immunity in an IL-9-
dependent fashion [23]. Mechanistically, TGF-β1 and IL-4
downregulate Id3 expression through TAK1 kinase. This re-
duction in Id3 expression enhances binding of the transcrip-
tion factors E2A and GATA-3 to the Il9 promoter region,
which promotes Il9 transcription [23]. Activation of GITR
by its ligand enhances IL-9 expression in a STAT6- and
NF-κB-dependent manner, followed by anti-cancer immune
responses [31, 32]. In the presence of IL-1β, IRF1 expression
is upregulated in a STAT1-dependent fashion. Subsequently,
IRF1 binds to the Il9 and Il21 promoters in TH9 cells, which
increases the secretion of both IL-9 and IL-21 [29].
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